Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peptide YY3-36 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Peptide YY3-36 | DRUG | - |
Inclusion Criteria: * BMI 27-35 kg/m2 Exclusion Criteria: * Women of childbearing potential
Top 20 of 35 competitors
Peptide YY3-36 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for obesity. It is a synthetic form of the peptide YY3-36 fragment and is being studied in the metabolic therapeutic area. It has completed a single Phase 1 clinical trial and is not approved for any use.
Peptide YY3-36 is being studied for obesity. The only clinical trial of the drug enrolled overweight adults, and the program is in Phase 1 development. It is investigational and has not been approved for the treatment of obesity or any other condition.
Peptide YY3-36 targets NPY2R, the neuropeptide Y2 receptor, where it acts as an agonist. By activating NPY2R, the drug is designed to influence appetite and metabolic signaling relevant to obesity. NPY2R is the receptor through which the natural peptide YY3-36 fragment signals.
Pfizer, Inc., which trades under the ticker PFE, is the developer of Peptide YY3-36. Pfizer sponsored the Phase 1 trial of the drug in overweight adults. The asset sits in Pfizer's metabolic pipeline and remains investigational.
Peptide YY3-36 is in Phase 1 development. It has completed one Phase 1 trial, and no later-stage trials are active. The drug is investigational and has not been approved by the FDA for obesity or any other indication.
Peptide YY3-36 has been studied in one completed Phase 1 trial, NCT00331175, titled Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults. The trial enrolled 31 participants in the United States, used a randomized design, and included healthy volunteers.